U.S. Markets

Johnson & Johnson (JNJ) to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology; will be USD 2.2bln upfront and USD 1.125bln in milestone payments

ORIGINAL · NewsquawkJohnson & Johnson (JNJ) to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology; will be USD 2.2bln upfront and USD 1.125bln in milestone paymentsRead originalHide original

Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema.

StockNow breaking-news AI analysis

J&J is acquiring Ollin Biosciences, adding Phase 3 candidate OLN324; Reuters had reported prior discussions of $2.2 billion upfront and $1.2 billion in potential milestones.

News detail

Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more